US7825121B2
(en)
*
|
1999-05-04 |
2010-11-02 |
Schering Corporation |
Piperazine derivatives useful as CCR5 antagonists
|
WO2002079157A1
(en)
|
2001-03-29 |
2002-10-10 |
Schering Corporation |
Aryl oxime-piperazines useful as ccr5 antagonists
|
DE60236218D1
(de)
|
2001-03-29 |
2010-06-10 |
Schering Corp |
CCR5 Antagonisten verwendbar für die Behandlung von Aids
|
US6943251B2
(en)
*
|
2001-11-29 |
2005-09-13 |
Schering Corporation |
Preparation of salts of 4-[4-[(1R)-[4-(trifluoromethyl)phenyl]-2-methoxyethyl]-(3S)-methyl-1-piperazinyl]-4-methyl-1-[(4,6-dimethyl-5-pyrimidinyl)carbonyl]
|
EP2311818B1
(en)
|
2002-02-28 |
2013-01-16 |
Novartis AG |
Combination of a 5-phenylthiazole compound as PI3 kinase inhibitor with an antiinflammatory, bronchodilatory or antihistamine drug
|
JP4671091B2
(ja)
*
|
2002-03-18 |
2011-04-13 |
東レ・ファインケミカル株式会社 |
1−置換−2−メチルピペラジンの製造方法
|
US6872826B2
(en)
|
2002-03-29 |
2005-03-29 |
Schering Corporation |
Stereoselective alkylation of chiral 2-methyl-4-protected piperazines
|
CN101139343A
(zh)
*
|
2002-03-29 |
2008-03-12 |
先灵公司 |
作为ccr5拮抗药的哌啶和哌嗪化合物的合成
|
EP1498125A4
(en)
*
|
2002-04-24 |
2008-08-20 |
Takeda Pharmaceutical |
USE OF ANTI-CCR ANTAGONISM COMPOUNDS
|
JP2003335737A
(ja)
|
2002-05-21 |
2003-11-28 |
Central Glass Co Ltd |
光学活性(r)−1−(4−トリフルオロメチルフェニル)エチルアミン
|
TW200504033A
(en)
|
2002-10-23 |
2005-02-01 |
Procter & Gamble |
Melanocortin receptor ligands
|
US20060251651A1
(en)
*
|
2002-12-13 |
2006-11-09 |
Ono Pharmaceutical Co., Ltd. |
Antagonist and agonist which bind to a strong binding site of chemokine receptor
|
PE20040769A1
(es)
*
|
2002-12-18 |
2004-11-06 |
Schering Corp |
Derivados de piperidina utiles como antagonisas ccr5
|
CN101928284A
(zh)
|
2003-03-14 |
2010-12-29 |
小野药品工业株式会社 |
含氮杂环衍生物以及包含所述化合物作为活性成分的药物
|
EP2364982A1
(en)
|
2003-04-18 |
2011-09-14 |
ONO Pharmaceutical Co., Ltd. |
Spiro-piperidine compounds as chemokine receptor antagonists and medicinal use thereof
|
WO2004092136A1
(ja)
*
|
2003-04-18 |
2004-10-28 |
Ono Pharmaceutical Co., Ltd. |
含窒素複素環化合物およびその用途
|
TW200519106A
(en)
|
2003-05-02 |
2005-06-16 |
Novartis Ag |
Organic compounds
|
BRPI0411414A
(pt)
*
|
2003-06-13 |
2006-07-25 |
Schering Ag |
derivados de quinolil amida como antagonistas de cdr-5
|
GB0313661D0
(en)
*
|
2003-06-13 |
2003-07-16 |
Avecia Ltd |
Process
|
JP4605801B2
(ja)
|
2003-06-30 |
2011-01-05 |
シェーリング コーポレイション |
肥満治療用のmchアンタゴニスト
|
US7652142B2
(en)
|
2003-11-03 |
2010-01-26 |
Schering Corporation |
Bipiperidinyl derivatives useful as inhibitors of chemokine receptors
|
GB0329284D0
(en)
*
|
2003-12-18 |
2004-01-21 |
Avecia Ltd |
Process
|
GB0401334D0
(en)
|
2004-01-21 |
2004-02-25 |
Novartis Ag |
Organic compounds
|
JP2007520556A
(ja)
*
|
2004-02-05 |
2007-07-26 |
シェーリング コーポレイション |
Ccr3アンタゴニストとして有用なピペリジン誘導体
|
BRPI0507586A
(pt)
*
|
2004-02-10 |
2007-07-03 |
Hoffmann La Roche |
moduladores de receptor de quimiocina ccr5
|
ES2526614T3
(es)
|
2004-03-05 |
2015-01-13 |
Nissan Chemical Industries, Ltd. |
Compuesto de benzamida sustituida con isoxazolina y agente de control de organismos nocivos
|
GEP20094680B
(en)
*
|
2004-04-13 |
2009-05-10 |
Incyte Corp |
Piperazinylpiperidine derivatives as chemokine receptor antagonists
|
RU2006146608A
(ru)
|
2004-06-09 |
2008-07-20 |
Ф.Хоффманн-Ля Рош Аг (Ch) |
ОКТАГИДРОПИРРОЛО[3,4-с]-ПРОИЗВОДНЫЕ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ПРОТИВОВИРУСНЫХ АГЕНТОВ
|
GB0417804D0
(en)
*
|
2004-08-10 |
2004-09-15 |
Novartis Ag |
Organic compounds
|
US8143404B2
(en)
*
|
2004-09-13 |
2012-03-27 |
Ono Pharmaceutical Co., Ltd |
Nitrogenous heterocylic derivative and medicine containing the same as an active ingredient
|
GT200500281A
(es)
|
2004-10-22 |
2006-04-24 |
Novartis Ag |
Compuestos organicos.
|
GB0426164D0
(en)
|
2004-11-29 |
2004-12-29 |
Novartis Ag |
Organic compounds
|
ES2435790T3
(es)
|
2004-12-03 |
2013-12-23 |
Intervet International B.V. |
Piperazinas sustituidas como antagonistas de CB1
|
US7635698B2
(en)
|
2004-12-29 |
2009-12-22 |
Millennium Pharmaceuticals, Inc. |
Compounds useful as chemokine receptor antagonists
|
WO2006071875A1
(en)
|
2004-12-29 |
2006-07-06 |
Millennium Pharmaceuticals, Inc. |
Compounds useful as chemokine receptor antagonists
|
CA2594109A1
(en)
|
2005-01-06 |
2006-07-13 |
Schering Corporation |
Preparation of pharmaceutical salts of piperazine compounds
|
CA2598458A1
(en)
|
2005-02-16 |
2006-08-24 |
Schering Corporation |
Pyrazinyl substituted piperazine-piperidines with cxcr3 antagonist activity
|
WO2006088836A2
(en)
*
|
2005-02-16 |
2006-08-24 |
Schering Corporation |
Piperazine-piperidines with cxcr3 antagonist activity
|
US7417045B2
(en)
|
2005-02-16 |
2008-08-26 |
Schering Corporation |
Heterocyclic substituted pyridine or phenyl compounds with CXCR3 antagonist activity
|
ATE523506T1
(de)
*
|
2005-02-16 |
2011-09-15 |
Schering Corp |
Amingebundene pyridyl- und phenylsubstituierte piperazin-piperidine mit cxcr3-antagonistischer aktivität
|
MX2007009946A
(es)
*
|
2005-02-16 |
2007-09-26 |
Schering Corp |
Piperazin-piperidinas sustituidas con piridilo y fenilo con actividad antagonista de cxcr3.
|
PE20061012A1
(es)
*
|
2005-02-23 |
2006-10-03 |
Schering Corp |
Derivados piperidinil piperazina como inhibidores de receptores quiomicina
|
GB0507577D0
(en)
|
2005-04-14 |
2005-05-18 |
Novartis Ag |
Organic compounds
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
JPWO2006129679A1
(ja)
|
2005-05-31 |
2009-01-08 |
小野薬品工業株式会社 |
スピロピペリジン化合物およびその医薬用途
|
KR100962732B1
(ko)
|
2005-06-02 |
2010-06-09 |
에프. 호프만-라 로슈 아게 |
피페리딘-4-일-아마이드 유도체 및 sst 수용체 아형 5길항제로서 그의 용도
|
US7665658B2
(en)
|
2005-06-07 |
2010-02-23 |
First Data Corporation |
Dynamic aggregation of payment transactions
|
BRPI0617720A2
(pt)
|
2005-10-19 |
2011-08-02 |
Hoffmann La Roche |
compostos inibidores de nnrt de fenil-acetamida, usos dos referidos compostos e composição farmacêutica que os contém
|
CA2625664C
(en)
|
2005-10-21 |
2016-01-05 |
Novartis Ag |
Human antibodies against il13 and therapeutic uses
|
PL1942108T3
(pl)
|
2005-10-28 |
2014-03-31 |
Ono Pharmaceutical Co |
Związek zawierający grupę zasadową i jego zastosowanie
|
JP5217438B2
(ja)
|
2005-11-18 |
2013-06-19 |
小野薬品工業株式会社 |
塩基性基を含有する化合物およびその用途
|
CA2629037A1
(en)
*
|
2005-11-30 |
2007-06-07 |
Schering Corporation |
Compositions comprising a combination of ccr5 and cxcr4 antagonists
|
GB0525671D0
(en)
|
2005-12-16 |
2006-01-25 |
Novartis Ag |
Organic compounds
|
GB0526244D0
(en)
|
2005-12-22 |
2006-02-01 |
Novartis Ag |
Organic compounds
|
CA2637565A1
(en)
|
2006-01-18 |
2007-07-26 |
Schering Corporation |
Cannibinoid receptor modulators
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
US8003642B2
(en)
|
2006-03-10 |
2011-08-23 |
Ono Pharmaceutical Co., Ltd. |
Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient
|
ATE549337T1
(de)
|
2006-04-21 |
2012-03-15 |
Novartis Ag |
Purinderivate zur verwendung als adenosin-a2a- rezeptoragonisten
|
US8618122B2
(en)
|
2006-05-16 |
2013-12-31 |
Ono Pharmaceutical Co., Ltd. |
Compound having acidic group which may be protected, and use thereof
|
WO2008016006A1
(en)
|
2006-07-31 |
2008-02-07 |
Ono Pharmaceutical Co., Ltd. |
Compound having cyclic group bound thereto through spiro binding and use thereof
|
RU2451676C2
(ru)
|
2006-08-16 |
2012-05-27 |
Ф.Хоффманн-Ля Рош Аг |
Ненуклеозидные ингибиторы обратной транскриптазы
|
WO2008037477A1
(en)
|
2006-09-29 |
2008-04-03 |
Novartis Ag |
Pyrazolopyrimidines as p13k lipid kinase inhibitors
|
RU2469032C2
(ru)
|
2006-12-13 |
2012-12-10 |
Ф.Хоффманн-Ля Рош Аг |
Производные 2-(пиперидин-4-ил)-4-фенокси- или фениламинопиримидина в качестве ненуклеозидных ингибиторов обратной транскриптазы
|
GB0625523D0
(en)
*
|
2006-12-21 |
2007-01-31 |
Ge Healthcare Ltd |
In vivo imaging agents
|
PL2104535T3
(pl)
|
2007-01-10 |
2011-05-31 |
Irm Llc |
Związki i kompozycje jako inhibitory proteazy aktywujące kanały
|
MY156814A
(en)
|
2007-03-15 |
2016-03-31 |
Novartis Ag |
Organic compounds and their uses
|
EP2142555A1
(en)
|
2007-03-29 |
2010-01-13 |
F. Hoffmann-Roche AG |
Heterocyclic antiviral compounds
|
ES2361595T3
(es)
|
2007-05-07 |
2011-06-20 |
Novartis Ag |
Compuestos orgánicos.
|
CA2687931C
(en)
|
2007-05-31 |
2016-05-24 |
Boehringer Ingelheim International Gmbh |
Ccr2 receptor antagonists and uses thereof
|
MX2010003621A
(es)
*
|
2007-10-01 |
2010-04-14 |
Hoffmann La Roche |
N-heterociclil biaril carboxamidas como antagonistas del receptor ccr.
|
MX2010006421A
(es)
|
2007-12-10 |
2010-06-25 |
Novartis Ag |
Compuestos organicos.
|
US20110059154A1
(en)
*
|
2008-02-29 |
2011-03-10 |
Strizki Julie M |
Ccr5 antagonists as prophylactics for preventing hiv infection and methods of inhibiting transmission of same
|
US8268834B2
(en)
|
2008-03-19 |
2012-09-18 |
Novartis Ag |
Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
|
WO2009128947A1
(en)
*
|
2008-04-17 |
2009-10-22 |
Concert Pharmaceuticals, Inc. |
Piperazine derivatives
|
BRPI0915018A2
(pt)
|
2008-06-10 |
2015-10-27 |
Novartis Ag |
compostos orgânicos
|
US20100041663A1
(en)
|
2008-07-18 |
2010-02-18 |
Novartis Ag |
Organic Compounds as Smo Inhibitors
|
BRPI0923051B1
(pt)
|
2008-12-19 |
2022-07-19 |
Centrexion Therapeutics Corporation |
Pirimidin-4-carboxamidas cíclicas como antagonistas do receptor de ccr2 para o tratamento de inflamação, asma e copd, seu uso, formulação e combinação farmacêutica que os compreende
|
WO2010088335A1
(en)
|
2009-01-29 |
2010-08-05 |
Novartis Ag |
Substituted benzimidazoles for the treatment of astrocytomas
|
WO2010129351A1
(en)
|
2009-04-28 |
2010-11-11 |
Schepens Eye Research Institute |
Method to identify and treat age-related macular degeneration
|
US8389526B2
(en)
|
2009-08-07 |
2013-03-05 |
Novartis Ag |
3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
|
BR112012003262A8
(pt)
|
2009-08-12 |
2016-05-17 |
Novartis Ag |
compostos de hidrazona heterocíclica e seus usos para tratar câncer e inflamação
|
IN2012DN01961A
(ja)
|
2009-08-17 |
2015-08-21 |
Intellikine Llc |
|
CA2771432A1
(en)
|
2009-08-20 |
2011-02-24 |
Novartis Ag |
Heterocyclic oxime compounds
|
EP2490687A1
(en)
|
2009-10-22 |
2012-08-29 |
Vertex Pharmaceuticals Incorporated |
Compositions for treatment of cystic fibrosis and other chronic diseases
|
US20130143905A1
(en)
*
|
2009-12-17 |
2013-06-06 |
Boehringer Ingelheim International Gmbh |
Novel antagonists for ccr2 and uses thereof
|
KR101530234B1
(ko)
|
2009-12-17 |
2015-06-19 |
베링거 인겔하임 인터내셔날 게엠베하 |
신규한 ccr2 수용체 길항제 및 이의 용도
|
US8247436B2
(en)
|
2010-03-19 |
2012-08-21 |
Novartis Ag |
Pyridine and pyrazine derivative for the treatment of CF
|
EP2569298B1
(en)
|
2010-05-12 |
2015-11-25 |
Boehringer Ingelheim International GmbH |
Novel ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
|
JP5646736B2
(ja)
|
2010-05-12 |
2014-12-24 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
新規ccr2受容体アンタゴニスト、これらの製造方法、及び薬物としてのこれらの使用
|
WO2011144501A1
(en)
|
2010-05-17 |
2011-11-24 |
Boehringer Ingelheim International Gmbh |
Ccr2 antagonists and uses thereof
|
JP5636094B2
(ja)
|
2010-05-25 |
2014-12-03 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Ccr2受容体アンタゴニスト
|
JP5721242B2
(ja)
|
2010-06-01 |
2015-05-20 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
新規ccr2アンタゴニスト
|
UA109786C2
(xx)
|
2010-07-14 |
2015-10-12 |
|
Гетероциклічні сполуки як агоністи ір-рецептора
|
US8372845B2
(en)
|
2010-09-17 |
2013-02-12 |
Novartis Ag |
Pyrazine derivatives as enac blockers
|
WO2012107500A1
(en)
|
2011-02-10 |
2012-08-16 |
Novartis Ag |
[1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
|
EP2678016B1
(en)
|
2011-02-23 |
2016-08-10 |
Intellikine, LLC |
Heterocyclic compounds and uses thereof
|
EP2731941B1
(en)
|
2011-07-15 |
2019-05-08 |
Boehringer Ingelheim International GmbH |
Novel and selective ccr2 antagonists
|
WO2013024022A1
(en)
|
2011-08-12 |
2013-02-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treatment of pulmonary hypertension
|
US8883819B2
(en)
|
2011-09-01 |
2014-11-11 |
Irm Llc |
Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
|
MX339302B
(es)
|
2011-09-15 |
2016-05-19 |
Novartis Ag |
3-(quinolin-6-il-tio)-[1,2,4]-triazolo-[4,3-a]-piridinas 6-sustituidas como cinasas de tirosina.
|
JP6165733B2
(ja)
|
2011-09-16 |
2017-07-19 |
ノバルティス アーゲー |
N−置換ヘテロシクリルカルボキサミド類
|
WO2013038381A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine/pyrazine amide derivatives
|
WO2013038378A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine amide derivatives
|
WO2013038386A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Heterocyclic compounds for the treatment of cystic fibrosis
|
WO2013038373A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine amide derivatives
|
WO2013078440A2
(en)
|
2011-11-23 |
2013-05-30 |
Intellikine, Llc |
Enhanced treatment regimens using mtor inhibitors
|
EP2802589B1
(en)
|
2012-01-13 |
2016-01-06 |
Novartis AG |
Fused pyrroles as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
|
WO2013105065A1
(en)
|
2012-01-13 |
2013-07-18 |
Novartis Ag |
Fused piperidines as ip receptor agonists for the treatment of pah and related disorders
|
EP2802582A1
(en)
|
2012-01-13 |
2014-11-19 |
Novartis AG |
Fused dihydropyrido [2,3 -b]pyrazines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
|
WO2013105058A1
(en)
|
2012-01-13 |
2013-07-18 |
Novartis Ag |
7,8- dihydropyrido [3, 4 - b] pyrazines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
|
US9174985B2
(en)
|
2012-01-13 |
2015-11-03 |
Novartis Ag |
Salts of 7-(2,3-di-p-tolyl-7,8-dihydropyrido[2,3-b]pyrazin-5(6H)-yl)heptanoic acid as IP receptor agonists
|
US20150005311A1
(en)
|
2012-01-13 |
2015-01-01 |
Novartis Ag |
IP receptor agonist heterocyclic compounds
|
US8809340B2
(en)
|
2012-03-19 |
2014-08-19 |
Novartis Ag |
Crystalline form
|
ES2894830T3
(es)
|
2012-04-03 |
2022-02-16 |
Novartis Ag |
Productos combinados con inhibidores de tirosina·cinasa y su uso
|
US9227990B2
(en)
|
2012-10-29 |
2016-01-05 |
Cipla Limited |
Antiviral phosphonate analogues and process for preparation thereof
|
JP2016507582A
(ja)
|
2013-02-13 |
2016-03-10 |
ノバルティス アーゲー |
Ip受容体アゴニスト複素環式化合物
|
US9073921B2
(en)
|
2013-03-01 |
2015-07-07 |
Novartis Ag |
Salt forms of bicyclic heterocyclic derivatives
|
WO2014151147A1
(en)
|
2013-03-15 |
2014-09-25 |
Intellikine, Llc |
Combination of kinase inhibitors and uses thereof
|
TW201605450A
(zh)
|
2013-12-03 |
2016-02-16 |
諾華公司 |
Mdm2抑制劑與BRAF抑制劑之組合及其用途
|
CA2945212A1
(en)
|
2014-04-24 |
2015-10-29 |
Novartis Ag |
Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
|
JP6404944B2
(ja)
|
2014-04-24 |
2018-10-17 |
ノバルティス アーゲー |
ホスファチジルイノシトール3−キナーゼ阻害薬としてのピラジン誘導体
|
MX2016013981A
(es)
|
2014-04-24 |
2016-11-15 |
Novartis Ag |
Derivados de amino-piridina como inhibidores de fosfatidil-inositol-3-cinasa.
|
WO2016011658A1
(en)
|
2014-07-25 |
2016-01-28 |
Novartis Ag |
Combination therapy
|
US10195208B2
(en)
|
2014-07-31 |
2019-02-05 |
Novartis Ag |
Combination therapy
|
CN107108581B
(zh)
*
|
2014-08-21 |
2020-06-23 |
百时美施贵宝公司 |
作为强效rock抑制剂的回接苯甲酰胺衍生物
|
CN108026087B
(zh)
|
2015-07-02 |
2021-06-04 |
中枢疗法公司 |
氨基嘧啶甲酮衍生物的柠檬酸盐
|
KR20220019015A
(ko)
|
2019-06-10 |
2022-02-15 |
노파르티스 아게 |
Cf, copd, 및 기관지확장증 치료를 위한 피리딘 및 피라진 유도체
|
WO2021038426A1
(en)
|
2019-08-28 |
2021-03-04 |
Novartis Ag |
Substituted 1,3-phenyl heteroaryl derivatives and their use in the treatment of disease
|
TW202140550A
(zh)
|
2020-01-29 |
2021-11-01 |
瑞士商諾華公司 |
使用抗tslp抗體治療炎性或阻塞性氣道疾病之方法
|
US11629196B2
(en)
|
2020-04-27 |
2023-04-18 |
Incelldx, Inc. |
Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions
|